• Lara Almudena Fernández Bermejo, Carlos Gutiérrez Ortega, and José Javier Jareño Esteban.
• Servicio de Medicina Interna, Hospital de la Fuenfría, Cercedilla, Madrid, España. Electronic address: larafernandezber@gmail.com.
• Med Clin (Barc). 2022 Mar 11; 158 (5): 201-205.

IntroductionThe aim of this study is to analyse comorbidity, survival, and mortality from pulmonary embolism (PE) in people with cancer and without cancer. And to determine whether the Charlson Comorbidity Index (CCI) predicts mortality in the short and long term in this population.MethodsA retrospective observational study on survival in patients hospitalized in the Hospital Central de la Defensa from 1-01-2009 to 15-03-2018, stratifying into tumour PE group (EPT) and non-tumour PE group (EPnT), all of whom were classified according to age adjusted CCI.ResultsA total of 368 patients were diagnosed with PE, 108 with associated cancer. The mean CCI in the EPT group was 7.2 and 4.5 in the EPnT group. Patients with PE and CCI>5 were 10.7 times more likely to die (95%CI 1.5-77.6) compared to CCI 0 (P=.019). The CCI of patients with EPT was 2.6 points higher (95%CI 1.9-33) than EPnT patients (P<.001). Cancer patients were 1.9 times more likely to die (95%CI 1.23-2.8) and had higher mortality at 30 days and at one year after the event, with a median survival of 8.98 years and 3.4 years, respectively (P<.001).ConclusionsThe CCI in EPT is an independent risk factor related to mortality. The CCI can predict higher mortality in the short and long term in patients with PE.Copyright © 2021 Elsevier España, S.L.U. All rights reserved.

22 keywords...

hide…